Vonoprazan Fumarate CAS 1260141-27-2 as known as TAK-438, a new oral anti-gastric drug, is mainly used for the treatment of erosive esophagitis, gastric ulcer and duodenal ulcer. It has a good effect in clinical trials, and has good tolerance and safety.
Vonoprazan Fumarate compared with similar traditional drugs have the following advantages: 1. Rapid onset, the first day of administration will achieve the greatest acid suppression effect 2. Oral administration, without damage by gastric acid. 3. Do some improvement on the phenomenon of acid breakthrough at night . 4. In the acidic environment, do not need acid activation, can be effective. Our company's Vonoprazan Fumarate does not sell to the patent protection area, otherwise the patent dispute will be responsible by the buyer.

Thera. Category:Anti-gastric

Cas No.: 1260141-27-2

Synonym:vonoprazan(tak-438);Vonoprazan fumarate(TAK-438); TAK-438;5-(2-Fluorophenyl)-N-methyl-1-(3-pyridinylsulfonyl)-1H-pyrrole-3-methanamine 2-butenedioate;Vonoprazan FuMarate;Vonaprazan;vonoprazan(tak-438)1260141-27-2;fuMarate vonoprazan;

Molecular Weight: 461.4634032

Molecular formula: C21H20FN3O6S

Assay: ≥98.%

Appearance: White Crystalline solid

Packing:Export worthy packing

Material Safety Data Sheet:Available on request

Related intermediate: 

1) 5-(2-fluorophenyl)-1H-pyrrole-3-carbaldehyde CAS number 881674-56-2

2) 1H-Pyrrole-3-carboxaldehyde, 5-(2-fluorophenyl)-1-(3-pyridinylsulfonyl)- CAS number is 881677-11-8